Hypoxia in biology and medicine: The legacy of L H Gray

British Journal of Radiology

Volumn 79, Issue 943, 2006, Pages 545-549

  Dendy, P P ^a   Wardman, P ^b  

^a Mount Vernon Hospital ^*  (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETANIDAZOLE; METRONIDAZOLE; MISONIDAZOLE; NIMORAZOLE; NITROIMIDAZOLE DERIVATIVE; OXYGEN; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

BLADDER CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CAREER; CLINICAL MEDICINE; CLINICAL TRIAL; DRUG HALF LIFE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; HYPOXIA; HYPOXIC CELL; IONIZING RADIATION; LUNG TUMOR; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; NONHUMAN; NOTE; RADIOBIOLOGY; SYSTEMATIC REVIEW; TUMOR NECROSIS; UNSPECIFIED SIDE EFFECT; X RAY;

CELL HYPOXIA; CLINICAL TRIALS, PHASE III; GENE EXPRESSION; GREAT BRITAIN; HISTORY, 20TH CENTURY; NEOPLASMS; RADIOBIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 33746174301     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/13634453     Document Type: Note

References (30)

1. Gray LH. The initiation and development of cellular damage by ionising radiations. Br J Radiol 1953;26:609-18.
2. Mottram JC. A factor of importance in the radiosensitivity of tumours. Br J Radiol 1936;9:606-14.
3. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
4. Tomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49.
5. Hall EJ. Radiobiology for the radiologist, 5th edn. Philadelphia, PA: Lippincott, Williams and Wilkins, 2000:108-9, 458.
6. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosenstizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46.
7. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
8. Pugh CF, Ratcliffe PJ. Regulation of angiogenesis by hypoxia - role of the HIF system. Nat Med 2003;9:677-84.
9. Koritzinsky M, Seigneuric R, Magognin MG, van der Beuchen T, Lambin P, Wouters BG. The hypoxic proteome is influenced by gene specific change in m-RNA transcription. Radiother Oncol 2005;76:177-86.
10. Kaanders JH, Wijffels KI, Marres HA, Ljungkvist AS, Pop LA, van den Hoogen FJ, et al. Pimonidazole binding and tumour vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-74.
11. van Laarhoven HWM, Bussink J, Lok J, Punt CJA, Heerschap A, van Der Kogel AJ. Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters. Int J Radiat Oncol Biol Phys 2004;60:310-21.
12. Bennewith KL, Durand RE. Quantifying transient hypoxia in human tumour xenografts by flow cytometry. Cancer Res 2004;64:6183-9.
13. Nöth U, Rodrigues LM, Robinson SP, Jork A, Zimmermann U, Newell B, Griffiths JR. In vivo determination of tumour oxygenation during growth and in response to carbogen breathing using 15C5 loaded alginate capsules as fluorine-19 magnetic resonance imaging oxygen sensors. Int J Radiat Oncol Biol Phys 2004;60:909-19.
14. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
15. Baumann M, Krause M. Targeting the epidermal growth factor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004;72: 257-66.
16. Krause M, Ostermann G, Petersen C, Yaromina A, Hessel F, Harstrick A, et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 2005;76:162-7.
17. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004;10:8587-93.
18. Zips D, Hessel F, Krause M, Schiefer Y, Hoinkis C, Thames HD, et al. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinase on tumour growth delay and local tumour control after fractionated irradiation of human squamous cell carcinoma in nude mice. Int J Radiat Oncol Biol Phys 2005;61:908-14.
19. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
20. Kaanders JH, Bussink J, van der Kogel AJ. ARCON A novel biology-based approach in radiotherapy. Lancet Oncol 2002;3:728-37.
21. Gray LH, Green FO, Howes CA. Effect of nitric oxide on the radiosensitivity of tumour cells. Nature 1958;182:952-3.
22. Dewey DL. The effect of oxygen and nitric oxide on the radiosensitivity of human cells in tissue culture. Nature 1960;186:780-2.
23. Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Khan MA, et al. Vascular endothelial growth factor and nitric oxide synthetase expression in human lung cancer and the relation to p53. Br J Cancer 1998;78:223-39.
24. Gray LH, Steadman JM. Determination of the oxyhaemoglobin dissociation curves for mouse and rat blood. J Physiol 1964;175:161-71.
25. Adams GE, Stratford 1J. Bioreductive drugs for cancer therapy - the search for tumour specificity. Int J Radiat Oncol Biol Phys 1994;29:231-8.
26. Choy H, Nabid A, Stea B, Scott C, Roa W, Kleinberg L, et al. Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5918-28.
27. Foster JL, Conroy PJ, Searle AJ, Willson RL. Metronidazole (Flagyl): characterization as a cytotoxic drug specific for hypoxic tumour cells. Br J Cancer 1976;33:485-90.
28. Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997;3:515-20.
29. Williams KJ, Telfer BA, Xenaki D, Sheridan MR, Desbaillets I, Peters HJ, et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 2005;75:89-98.
30. Loutit JF, Scott OCA. Louis Harold Gray 1905-1965. Elected F.R.S. 1961. Biogr Mem Fellows R Soc 1966;12:195-217.